Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

This study is testing an off-the-shelf CAR-T cell therapy — engineered immune cells designed to recognize and attack multiple myeloma cancer cells — in patients whose myeloma has come back or stopped responding to prior treatments. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with multiple myeloma (a blood cancer affecting plasma cells) - Your myeloma has relapsed (come back) or is refractory (not responding) to previous treatments - Your disease is still measurable on blood or urine protein tests - Your general health and organ function meet minimum requirements (ECOG score 0-2, expected survival more than 3 months) **You may NOT be eligible if...** - You have not had prior myeloma treatment, or your disease has not yet relapsed or become refractory - You have serious ongoing side effects from prior therapies (above grade 2) - Your blood counts or organ function are below acceptable levels - You have conditions that make you unable to safely undergo this treatment Talk to your doctor to see if this trial is right for you.